Topic Listing for Gen-Probe

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income Loss
Accumulated Other Comprehensive Loss Income Acquire Other Businesses Form Collaborations Strategic Alliances Joint
Adoption Fin Adoption Recent Accounting Pronouncements
Agreement Novartis Formerly Chiron Corporation Agreement Siemens Healthcare Diagnostics Inc Formerly Bayer Corporation
Agreement Siemens Medical Solutions Diagnostics Inc Formerly Bayer Agreements Molecular Profiling Institute Inc
Agreements Stratec Amendment Novartis Agreement
Annual Cash Bonus Annual Cash Bonus Awards
Annual Report Anti-takeover Provisions Certificate Incorporation By-laws Delaware Law Delay
Assets Liabilities Measured Fair Value Non-recurring Basis Assets Liabilities Measured Fair Value Recurring Basis
Audit Committee Available-for-sale Securities
Base Salary Bayer Corporation Now Siemens Healthcare Diagnostics Inc
Bayer Corporation Now Siemens Medical Solutions Diagnostics Inc Because Depend Small Number Customers Significant Portion Total
Beneficial Owner Shares Registered Name Broker Bank Beneficial Ownership Reporting Compliance
Biological Hazardous Materials Manner Causes Injury Violates Laws Biomérieux Vitek Inc
Blood Screening Products Brand Recognition
Capitalized Software Costs Cash Equivalents
Certain Related Person Transactions Change Vote After Submitting Proxy
Changes Internal Control Over Financial Reporting Clinical Diagnostic Products
Clinical Diagnostic Products Detection Markers Cancer Clinical Diagnostic Products Detection Viral Microorganisms
Code Ethics Collaboration Agreement Gei
Collaboration Agreement Millipore Collaboration Agreements Develop Nat Products Industrial Testing Applications
Collaborative Research Revenue Collectibility Accounts Receivable
Compensation Benchmarking Peer Group Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Processes Procedures
Compensation Committee Report Compensation Discussion Analysis
Competition Competitive Strengths
Compliance Changing Corporate Governance Public Disclosure Regulations Result Concentration Credit Risk
Conclusion Regarding Effectiveness Disclosure Controls Procedures Contents
Contingencies Contract Manufacturers Unable Manufacture Products Sufficient Quantities Timely
Contractual Obligations Commercial Commitments Corporate Collaborations
Corporate Governance Guidelines Corporation
Cost Product Sales Cost Revenues
Cuda Instrument System Customers
Customers Subject Various Governmental Regulations Incur Significant Expenses Deferred Compensation Plan
Deliver Proprietary Automated Fully Integrated Systems Nat Assays Dependent Novartis Other Parties Distribution Some Products Distributors
Dependent Technologies License Fail Maintain Licenses New Rights Description 2002 New Hire Plan
Determination Compensation Awards Diagnostic Products Industry History Patent Other Intellectual Property
Did Receive One-page Notice Mail Regarding Internet Availability Digene Corporation
Director Compensation Director Continuing Office Until 2010 Annual Meeting Stockholders
Directors Continuing Office Until 2008 Annual Meeting Stockholders Directors Continuing Office Until 2009 Annual Meeting Stockholders
Directors Continuing Office Until 2010 Annual Meeting Stockholders Directors Continuing Office Until 2011 Annual Meeting Stockholders
Disruptions Supply Raw Materials Consumable Goods Single Source Distribution Agreement Rebio Gen
Distributors Documents Incorporated Reference
Dts 400 800 1600 Instruments Eitf 07-1
Eitf 07-3 Eitf Issue 07-1
Eitf Issue 07-3 Employee Stock Purchase Plan
Employees Employment Agreement Chief Executive Officer
Employment Agreement President Chief Operating Officer Employment Agreements Executive Officers
Employment Agreements Other Named Executive Officers Equity Awards
Equity Compensation Plan Information Equity Investment Private
Establish Leadership Positions New Markets Leveraging Core Technologies Estimates
Exact Name Registrant Specified Charter Exclusive Development Supply Agreement
Executive Compensation Philosophy Executive Officers
Expand Clinical Diagnostics Blood Screening Businesses New Products Expand Core Clinical Diagnostics Blood Screening Businesses New
Expect Continue Incur Significant Research Development Expenses Make Exposed Risks Associated Acquisitions Other Long-lived Intangible Assets
Extensive Range Fda-approved Products Intellectual Property Portfolio Face Intense Competition Failure Compete Effectively Decrease Revenues
Fail Attract Hire Retain Qualified Personnel Not Able Failure Manufacture Products Accordance Product Specifications Result Increased
Fair Value Financial Instruments Fin
Final Payment Received Litigation Settlement Financial Performance Adversely Affected Current Global Economic Conditions
Financial Results Find Out Results Voting Annual Meeting
Fold Detach Here Forecasts Other Forward Looking Statements Based Various Assumptions
Foreign Currencies Foreign Currency Exchange Risk
Forward-looking Statements Future Accounting Requirements
Future Changes Financial Accounting Standards Practices Existing Taxation Future Success Depend Part Ability Enhance Existing Products
Gen-probe Incorporated Gen-probe Incorporated Table Contents Form 10-k 2006 Index
Gen-probe Incorporated Table Contents Form 10-k 2007 Index Gen-probe Incorporated Table Contents Form 10-k 2008 Index
General Administrative General Terms 2002 Plan Awards
Government Regulation Grants Plan-based Awards
Gross Profit Margin Percentage Sale Blood Screening Assays Growth Strategy
Householding Proxy Materials Impact Sfas 123
Impairment Long-lived Assets Income Tax
Income Tax Expense Income Taxes
Independence Board Directors Industry Growth Trends
Information Regarding Committees Board Directors Information Sfas 123 Periods Prior 2006
Information Technology Systems Implementation Issues Disrupt Internal Operations Innovative Product Research Development
Instrumentation Intangible Assets
Intellectual Property Rights Rely Protect Technologies Underlying Products Inventories
Issuer Purchases Equity Securities Lease Commitments
Leased Facilities Leased Facility
License Agreements Licenses Obtained Third-party Technology
Licenses Technology Granted Other Companies Licensing
Litigation Long-lived Assets
Luminometers Managements Report Internal Control Over Financial Reporting
Manufacturing Raw Materials Market Information
Marketing Sales Marketing Strategy
Meetings Board Directors Millipore Corporation
Named Executive Officer Annual Cash Bonus Awards Natural Man-made Disaster Strikes Manufacturing Facilities Unable Manufacture
Net Income Per Share Nominating Corporate Governance Committee
Nominees Election Board Directors Three-year Term Expiring 2010 Nominees Election Board Directors Three-year Term Expiring 2011
Nominees Election Board Directors Three-year Term Expiring 2012 Nonqualified Deferred Compensation
Nonqualified Deferred Compensation 2006 Nonqualified Deferred Compensation 2007
Nonqualified Deferred Compensation 2008 Not Effectively Manage Growth Affect Ability Pursue Opportunities
Not Financing Future Capital Requirements Prevent Addressing Gaps Not Successfully Integrate Acquired Businesses Technologies
Notice Annual Meeting Stockholders Held 2007 Notice Annual Meeting Stockholders Held 2008
Notice Annual Meeting Stockholders Held 2009 Novartis
Novartis Formerly Chiron Corporation Offer Acquire Tepnel Life Sciences
Only Third-party Manufacturer Each Instrument Product Lines Exposes Open Door Policy
Option Exercises Stock Vested Option Exercises Stock Vested 2006
Option Exercises Stock Vested 2007 Option Exercises Stock Vested 2008
Organization Organization Basis Presentation
Other Benefits Other Matters
Outstanding Equity Awards Year-end Overview
Panther Instrument System Part
Patent Costs Patents Proprietary Rights
Paying Proxy Solicitation Pension Benefits
Policies Respect Equity Compensation Awards Policies Respect Equity Compensation Awards Ownership
Post-employment Compensation Post-termination Benefits
Pre-approval Policies Procedures Principal Accountant Fees Services
Principles Consolidation Pro Forma Information Periods Prior Adoption Sfas 123
Product Categories Compete Product Development
Product Development Recent Events Product Sales
Products Products Emerging Diagnostic Industrial Testing Applications
Products Subject Recalls Even After Receiving Fda Approval Property Plant Equipment
Proposal Proprietary Core Technologies
Purchase Commitments Pursue Collaborative Relationships Accelerate New Product Development Enhance
Pursue Future Licensing Acquisition Opportunities Quality Systems
Quarterly Revenue Operating Results Vary Significantly Future Periods Receiving Materials
Recent Events Recently Entered Collaboration Agreements Develop Nat Products Industrial
Reclassifications Regulatory Quality Assurance Experience
Related-person Transactions Policy Procedures Report Audit Committee Board Directors
Report Independent Registered Public Accounting Firm Research Agreement Gsk
Research Development Revenue Recognition
Revenues Revoke Change Vote After Submitting Proxy
Role Membership Compensation Committee Royalty Commitments
Royalty License Revenue Sales International Markets Subject Additional Risks
Sales Strategy Sales Technical Support Capabilities
San Diego California 92121 Schedule Valuation Qualifying Accounts
Schedule Valuation Qualifying Accounts 2007 Securities Exchange Act 1934
Segment Information Self-insurance Reserves
Sfas 141 Sfas 157
Sfas 159 Sfas 160
Shipping Handling Expenses Short Term Investments Subject Market Investment Risks Result
Short-term Investments Signatures
Special Awards Committee Stock Options
Stock Repurchase Program Stock-based Compensation
Stockholder Communications Board Directors Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Stockholder Rights Plan
Subject Future Product Liability Claims Exceed Scope Amount Succession Planning Committee
Summary Compensation Table Supply Agreement
Supply Purchase Agreement Supply Purchase Agreement Roche
Tax Considerations Technology
Third-party Payors Not Reimburse Customers Clinical Diagnostic Products Tigris Instrument Reliability Not Meet Market Expectations Unable
Tigris Instrument System Tosoh
Total Other Income Net Trademarks Trade Names
Valuation Goodwill Valuation Goodwill Long-lived Assets
Valuation Inventories Voluntary Counterbid Acquire Innogenetics
Vote Vote Annual Meeting
Votes Votes Counted
Votes Needed Approve Each Proposal What Broker Non-votes
What Mean Receive Notice Internet Availability Proxy Materials What Mean Receive Proxy Card
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Voting 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki